Skip to content
DataLookout
Menu

CAREMM-014NCT07903623

QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Minimal residual disease (MRD) negative rate
Timeframe: After 9 cycles (each cycle is 28 days)

Secondary (6)

Incidence and severity of adverse events (AEs)
Duration of MRD negativity
Overall Response Rate (ORR)
Complete Response Rate (CRR)
Progression-free survival (PFS)
Show 1 moreShow less
Overall survival (OS)

Arms and interventions

QLS4131 Plus IsatuximabExperimental

Participants will receive QLS4131 in combination with isatuximab for up to 18 cycles, with each cycle lasting 28 days.

Drugs: QLS4131, Isatuximab

Sites

1 site in 1 country

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, Tianjin Municipality, China